INTRODUCTION
============

With greater than 55,000 representative compounds, isoprenoids (also referred to as terpenes) are the largest and most chemically diverse family \[[@R1]\]. Isoprenoids are classified into groups according to the number of carbon atoms they contain, and include: hemiterpenes (C~5~), monoterpenes (C~10~), sesquiterpenes (C~15~), diterpenes (C~20~), triterpenes (C~30~), tetraterpenes (C~40~) and so forth. They play numerous functional roles in primary metabolic processes that are necessary for cell survival including cell wall and membrane biosynthesis (phytosterols), electron transport (plastoquinones), photosynthetic pigments (carotenoids), and hormones in plants (gibberellins) \[[@R2],[@R3]\]. In addition, microbial production of isoprenoids has found their way into industry as a source for nutraceuticals, pharmaceuticals and, most recently, in biofuel applications \[[@R4]\]. Some examples include fragrances and essential oils (menthol, eucalyptol, limonene), cosmetics (squalene), disinfectants (pinene and camphor), antimicrobials (taxol and artimesinen), food supplements (Vitamins A, E and K), food colorants (xanthanins), fuels (farnesene and botryococcenes) and dozens more of related industrial applications.

The chemistry of isoprenoid biosynthesis allows for a tremendous structural diversity within its members, both in terms of the carbon length of the molecule (*e.g.* monoterpenes, diterpenes) and in the connectivity observed in the isoprenoid chain after biosynthetic steps which process diphosphates (*e.g.* cyclization of a triterpene, condensation of two sesquiterpene diphosphates). Understandably, this chemical diversity has enabled members of the isoprenoid family to play a wide range of important biological roles throughout nature as previously mentioned. However, the biology of isoprenoid molecules is beyond the scope of this review. Generally speaking, research into isoprenoid chemistry includes work that aims to understand their role in endogenous biological pathways of relevance to human health (two such examples are the enzymology of cholesterol biosynthesis and the role of protein farnesylation in cancer progression), as well as work which is designed to isolate and characterize isoprenoid secondary metabolites of value to society (*e.g.* anticancer agents such as Taxol, or potential renewable fuels such as isoprene, farnesene, or botryococcenes), human health, plant and fungal biochemistry. Thus, the development of chemical routes to isoprenoid compounds aids the synthesis of some pharmacologically-valuable compounds and intermediates (many of which themselves represent challenging synthetic targets) as well as enables enzymological characterization and inhibition studies. In this review, we will focus primarily on synthetic routes that have been developed for isoprenoid intermediates for the purpose of enzyme discovery and characterization.

The chemical diversity of all isoprenoids is derived from one of two simple C~5~ building blocks: isopentenyl diphosphate (IPP) and its isomer dimethylallyl diphosphate (DMAPP). These universal precursors are produced by either of two routes: the mevalonate or the 2*C*-methyl-D-erythritol 4-phosphate (MEP) (also known as the non-mevalonate or 1-deoxy-D-xylulose 5-phosphate, DXP) pathway (Scheme **[1](#S1){ref-type="scheme"}**). Both biosynthetic routes are distributed throughout nature, and as a general rule of thumb the mevalonate pathway is prevalent in eukaryotes and archaea, whereas the MEP pathway is widespread in eubacteria. For this review, the synthetic intermediates found as part of the mevalonate pathway will not be discussed. Briefly, the MEP pathway begins with condensation of glyceraldehyde-3-phosphate (G3P) and pyruvate to generate DXP through the action of deoxyxylulose phosphate synthase (DXS) \[[@R5]\]. DXP then undergoes a carbon skeleton rearrangement and a NADPH-dependent reduction catalyzed by MEP synthase, which represents the first committed step in the MEP pathway \[[@R6]\]. Addition of cytidyl monophosphate (CMP) to MEP *via* the action of a CTP-dependent (CDPME) synthase \[[@R7]\], followed by activation of the tertiary alcohol to the tertiary phosphate (CDPME2P) with an ATP-dependent kinase \[[@R8]\] results in the cyclized product, methylerythritol-2,4-cyclodiphosphate (cMEPP), catalyzed by the similarly named synthase \[[@R9]\]. The final two steps each involve the reductive elimination of water, first through the action of cMEPP reductase to provide hydroxydimethylallyl disphosphate (HDMAPP) followed by HDMAPP reductase that result in the formation of both IPP and DMAPP \[[@R10]\]. IPP isomerase (IDI) interconverts IPP and DMAPP to provide the appropriate ratios for normal cellular function \[[@R11]\]. Condensation of the two C~5~-building blocks catalyzed by geranyl diphosphate synthase (GPPS) provides the monoterpene, GPP. This C~10~ subunit is the building block for the thousands of monoterpenes discovered thus far, a few of which are represented in this review. Addition of another IPP to the GPP framework by farnesyl diphosphate synthase (FPPS) results in the C~15~ foundation from which thousands of sesquiterpenes and triterpenes are found in Nature. Finally, geranylgeranyl diphosphate synthase (GGPPS) catalyzes the condensation of another IPP subunit to the FPP framework to provide GGPP, which is a precursor for many naturally occurring antioxidants, for example β-carotene. While not exhaustive, for there are scores of synthetic routes to varying chain-length isoprenoids and isoprenoid precursors, this review will focus on the syntheses of MEP pathway intermediates to the universal precursors, IPP and DMAPP, followed by representative synthetic routes to longer branched, unsaturated hydrocarbons that may be of interest to the reader.

Isoprenoid Precursors-Methylerythritol Phosphate (MEP) Pathway
==============================================================

Since the MEP pathway discovery to isoprenoids in the early 90s, considerable effort toward elucidating the enzymes responsible for their biosynthesis ensued \[[@R6],[@R12],[@R13]\]. Early studies revealed the MEP pathway was distributed in most bacteria, the chloroplasts of photosynthetic organisms, unicellular eukaryotes (*e.g.* green algae) and the malaria parasite \[[@R14]\]. Most importantly, the MEP pathway enzymes are excellent targets for the development of antimicrobial agents for there are no known human orthologs \[[@R15]\]. The first enzyme in the MEP pathway to isoprenoids, deoxyxylulose phosphate synthase, converts pyruvate and glyceraldehyde-3-phosphate to (--)-1-deoxy-D-xylulose 5-phosphate (DXP). Conversion of DXP to MEP through MEP synthase represents the first committed step to all isoprenoids where the mevalonate pathway is not present. Therefore, a fundamental understanding of the biological role of MEP synthase was exhaustively pursued, largely through the use of synthetic (isotopically-labeled) DX(P) substrates and corresponding substrate analogs.

Many examples for the enzyme-assisted synthesis of both DX and DXP and the corresponding isotopomers are reported in the literature \[[@R16]-[@R19]\]. However, preparation of large quantities of these deoxyxyluloses is not the preferred route largely due to purification problems, the requirement for expensive labeled precursors and scalability. In addition, biosynthetic production of DX(P) analogs is largely unattainable due to the stringent substrate specificity of the corresponding enzymes responsible for their biosynthesis. Therefore, synthetic preparations to these compounds are preferred due to the versatility of the chemical transformations from relatively cheap starting material, high-yielding reactions, and simple purifications.

*Syntheses of 1-deoxy-D-xylulose* **4**(DX)-The first examples for the synthesis of the D-enantiomer of DX were reported by Estramareix *et al.*in the early 80s. Following protection and oxidative cleavage of D-arabinitol **1**, condensation of isopropylidene-protected D-glyceraldehye and the acetaldehyde dithioacetal anion provided a mixture of the protected threose and erythro-isomers. Separation of the threose enantiomer from the erythro-form followed by deprotection provided D-deoxylulose **4**over three steps in 15% yield \[[@R20]\]. The same group improved upon the synthesis to deoxyxylulose and the 1-^2^H~3~-isotopically-labeled derivativethrough condensation of aldehyde **2**with methylmagnesium iodide to provide the 2,4-*O-*benzylidene-D-threose intermediate **3**. Following oxidation and deprotection, the free sugar **4** was obtained by brominolysis of the distannylidene derivative (Scheme **[2](#S2){ref-type="scheme"}**) \[[@R21],[@R22]\].

Importantly, the Grignard reaction for introduction of the methyl group is now the most widely used method for incorporation of isotopes into the C-1 position of deoxyxylulose (phosphate). Further, Estramareix *et al.*provided the foundation for future synthetic efforts through exploitation of the D-threose scaffold in order to set the correct stereochemistry in the final product. As such, multiple independent routes to the free sugar using either D-threose or its oxidized derivative, D-tartrate, were employed and overall yields were much improved \[[@R23]-[@R25]\], with the highest reported yield of 68% over five steps from dimethyl-D-tartrate \[[@R26]\]. A generalized reaction scheme for DX **4** syntheses from multiple laboratories starting from either the D-tartrate **5**or D-threitol **6** derivatives are outlined below (Scheme **[3](#S3){ref-type="scheme"}**).

The previously outlined synthetic routes to DX provide a convenient platform for incorporation of a stable isotope (^2^H or ^13^C) into the C-1 position of the free sugar *via* an aldehyde intermediate. However, incorporation of an isotopic tag at other positions along the polyol backbone is not feasible using these approaches. An alternative strategy was adopted by Giner *et al.*that enabled insertion of deuterium at the C-3 and/or C-4 positions of DX. Briefly, deuterium-hydrogen exchange of the phosphonium ylide **7** with a 10:1:1 mixture of CH~2~Cl~2~:D~2~O:CD~3~OD followed by a Wittig reaction with the benzyl-protected glycoaldehyde **8**provided the conjugated 5-carbon enone **9**with 85% deuterium incorporation at the C-3 position. Subsequent Sharpless asymmetric dihydroxylation and debenzylation *via* hydrogenolysis provided the enantiomerically pure DX **4**in good yields \[[@R27]-[@R29]\]. Conversely, the deuterium was conveniently inserted into the C-4 position (\~70% deuterium) by reduction of the propargyl alcohol **10**with lithium aluminum deuteride, followed by oxidation, asymmetric dihydroxylation then deprotection, although yields were not reported for the reduction step \[[@R24]\]. The authors also demonstrated incorporation of a ^13^C-label into the C-1 position of aldehyde **11**to provide 1-^13^C-DX **4** in 52% yield over four steps through enone intermediate **12**(Scheme **[4](#S4){ref-type="scheme"}**).

A convenient chemoenzymatic synthesis for 1-deoxy-5,5-^2^H~2~-D-xylulose was outlined by Piel and Boland starting from 2,3-*O*-isopropylide-dimethyl-D-tartrate. Briefly, pig liver esterase was used to convert the starting material to the monoester. Following reduction of the ester to the alcohol with LiBEt~3~D, methylation of the acid and deprotection of the isopropylidene moiety, the C-5 dideuterated DX was synthesized over four steps in 37% yield \[[@R30]\]. However, scalability was an issue since the first step required the use of the esterase.

*Syntheses of 1-deoxy-D-xylulose 5-phosphate* **16**(DXP), *isotopomers*, *and fluorinated analogs*-The first report for the synthesis of enantiomerically pure DXP was outlined by Begley *et al.*in 1998 \[[@R31]\]. The key step in this synthesis was desymmetrization of the *C*~2~-symmetric dibenzylated-D-threitol by monophosphorylation with dibenzylchlorophosorochloridate in 40% yield. The primary alcohol was converted to the methyl ketone using modified procedures previously outlined then debenzylation *via* hydrogenolysis provided DXP over seven steps in 5% yield from diethyl-D-tartrate. Shortly thereafter, Blagg and Poulter reported a more efficient chemical synthesis for DXP by exploiting (--)-2,3-*O*-isopropylidene-D-threitol **13** as a more suitable starting material for the chemical transformations (Scheme **[5](#S5){ref-type="scheme"}**). The triisopropylsilyloxy-protected DX **14**proved to be a versatile intermediate in the synthesis. Simple deprotection under acidic conditions provided DX **4**over five steps in 69% yield. Alternatively, following ketolization of the ketone with ethylene glycol and removal of the triisopropylsilyloxy-protecting group, the primary alcohol **15** was phosphorylated with trimethylated phosphite in the presence tellurium (IV) chloride. Phosphate deprotection in the presence of TMSBr followed by acidic workup and purification by cellulose chromatography provided pure DXP **16**in four steps from the fully protected DX in 71% yield \[[@R26]\].

MEP synthase is generally recognized as an excellent target for the development of novel antimicrobial agents. However, the enzyme-catalyzed reaction mechanism for conversion of DXP to MEP remained elusive. In order to address this gap, multiple isotopically-labeled DXP and DXP analogs were synthesized to determine the stereochemical course for the transformation. In 2003, Cox *et al.*reported a synthetic route to DXP from propargyl diol **17** where deuterium was incorporated into either the C3-**18**or C4-**19** positions, respectively, using a modified protocol reported by Giner *et al.*\[[@R32]\]. Silyl deprotection and selective phosphorylation of the primary alcohol over the secondary alcohol provided **20**and **21**, respectively. However, the overall yield and enantiopurity was suboptimal (\~20%, 84% e.e.) and no demonstration for isotopic label incorporation was discussed \[[@R33]\]. The same authors amended their synthesis for incorporation of the deuterium label into either the \[**3-^2^H\]-16** or \[**4-^2^H\]-16**position of DXP over eight steps in 15% or 7% yield (Scheme **[6](#S6){ref-type="scheme"}**), respectively, and corroborated previous reports that MEP synthase converts DXP to MEP through a retroaldol/aldol mechanism \[[@R34]-[@R36]\]. Shortly thereafter, Liu *et al.*reported two independent routes to the identical compounds with similar yields (\~8%, 95% e.e.) \[[@R37]\].

There are countless reports in the literature for the synthesis of DXP analogs that extend beyond the scope of this review. However, one class of DXP analogs deserves discussion since they were designed for three reasons: potential as novel inhibitors, determination of the enzyme-catalyzed reaction mechanism, and substrate specificity. Specifically, the fluorinated analogs of either DX or DXP were chemically synthesized for this purpose. The first report of a fluorinated deoxyxylulose analog was reported by Bouvet and O'Hagan for the synthesis of both 1-fluoro and 1,1-difluoro-1-deoxy-D-xylulose \[[@R38]\]. In their synthesis of the mono-fluorinated analog **24**, the authors utilized a Wittig reaction for coupling of the silyl-protected glycoaldehyde **22** with the mono-fluorinated phosphorous ylide **23**in a reaction analogous to previous reports for the \[3- and \[4-^2^H\]-DX syntheses \[[@R29]\]. However, Sharpless asymmetric dihydroxylation was unsuccessful thus necessitating standard dihydroxylation with osmium tetraoxide to provide the racemic fluorinated diol **25**. Deprotection of the silyl group provided the (±) C-1 monofluorinated DX in 30% yield over three steps as a 3:2 mixture of the α- and β-cyclic fluorinated anomers **26**and **27** (Scheme **[7](#S7){ref-type="scheme"}**).

Using O'Hagan's syntheses as an inspiration, Fox and Poulter synthesized the 1-fluoro-, 1,1-difluoro- and 1,1,1-trifluoromethyl-1-deoxy-D-xylulose 5-phosphate analogs for mechanistic studies with MEP synthase \[[@R39]\]. Upon installation of the oxirane moiety into aldehyde **28**, the key step in the synthesis of the 1-fluoromethyl-DXP (CF-DXP) was the regioselective ring opening of the intermediate oxirane **29** with diisopropylamine trihydrogen fluoride \[[@R40]\] at the C-1 position to provide the monofluorinated alcohol **30**in 45-55% yield. Debenzylation followed by regioselective phosphorylation of the primary alcohol with dibenzyl phosphoroiodidate and subsequent Dess-Martin oxidation provided the fully protected CF-DXP. Debenzylation of the phosphate by hydrogenolysis in *tert*-butanol instead of methanol or ethanol was necessary to avoid formation of the stable hemiketal due to the presence of the adjacent fluorine. The free acid effectively removed the isopropylidene moiety to provide CF-DXP **31** in 10% yield, with greater than 95% purity, over nine steps as a mixture of the ketone and hydrate forms (77:23) (Scheme **[8](#S8){ref-type="scheme"}**). A much lengthier synthesis of the identical compound was independently reported by Liu and coworkers. In their synthesis of 1-fluoromethyl-DXP, fluorination of the primary alcohol, which was derived from D-arabinose in three steps, with triflate and tetrabutylammonium fluoride (TBAF) provided the monofluorinated sugar. Deprotection of the 1,2-diol, benzylation and reductive ring opening with sodium borohydride provided the open chain-polyol. Regioselective benzyolation of the primary alcohol and Swern oxidation resulted in the fully protected monofluorinated deoxyxylulose. A series of protection and deprotection steps allowed for the introduction of the phosphate group with trimethyl phosphite in the presence of tellurium chloride and 2,6-lutidene to afford the protected CF-DXP. Deprotection of the phosphate methyl groups with TMSBr followed by debenzylation by hydrogenolysis provided the free acid of CF-DXP **31**. This compound was estimated to be 80% pure as judged by ^19^F NMR spectroscopy and was obtained in less than 3% yield over 14 steps \[[@R36]\]. In the same manuscript, Liu *et al.*described the synthesis of either the C-3 or C-4 monofluorinated DXP. These synthetic routes were a modified procedure as outlined for the C-1 monofluorinated DXP, required over 15 steps and the final material was obtained in low yields.

Simple modification of O'Hagan's synthesis for the 1,1-difluoromethyl deoxyxylulose, *via* the identical difluoromethylenephosphonate intermediate **33**, provided 1,1-difluoro-1-deoxy-D-xylulose 5-phosphate **35** over five steps from the isopropylidene-protected D-tartrate **5**. The key difference was installation of the dibenzyl phosphate into the tartrate monoester **32** prior to reaction with the lithiated diethyl(difluoromethyl)phosphonate. C-P bond cleavage of the phosphonate sugar **33**, after azeotropic removal of water, with sodium methoxide provided the fully protected CF~2~-DXP **34** in 83% yield. Deprotection provided the difluorinated sugar phosphate **35** in 53% yield over five steps from the tartrate monoester as a mixture of the ketone/hydrate (2:98) as judged by ^19^F NMR spectroscopy (Scheme **[9](#S9){ref-type="scheme"}**).

The key step in the synthesis of 1,1,1-trifluoromethyl-1-deoxy-D-xylulose 5-phosphate (CF~3~-DXP) was insertion of the trifluormethyl moiety into the identical TIPS-protected aldehyde intermediate found in Blagg's synthesis of DXP \[[@R26]\] using (trifluoromethyl)trimethylsilane and a catalytic amount of *tert*-butoxide, following a procedure outlined by Olah *et al.* \[[@R41]\], to provide the bissilyl ether as a 3:1 mixture of diastereomers. Following removal of the silyl ethers with two equivalents of TBAF, regioselective phosphorylation of the primary alcohol was carried out analogous to the synthesis for the monofluorinated DXP derivative. Deprotection using the same strategy as for the mono- and difluorinated DXP analogs afforded the trifluorinated sugar phosphate exclusively as the ketone hydrate in 46% yield over eight steps and greater than 95% purity as judged by ^19^F NMR spectroscopy.

*Syntheses of 2C-methyl-D-erythritol* **40**(ME)-The five carbon phosphosugar 2*C*-methyl-D-erythritol 4-phosphate is the first committed intermediate in the mevalonate-independent route, or MEP pathway, to isoprenoid compounds. The methylerythritol sugar is also known to be recognized, imported and incorporated into (after *in vivo* phosphorylation to form MEP) the isoprenoid products of various prokaryotes \[[@R42],[@R43]\]. Thus, synthetic preparations of ME and isotopically-enriched ME proved crucial to the efforts to identify the enzymes responsible for IPP and DMAPP biosynthesis through the MEP pathway \[[@R44],[@R45]\]. More recently, preparations of ME were instrumental in the discovery of its ability to act as a small-molecule stimulant of isoprenoid biosynthesis \[[@R46]\], and in studies of its influence upon plant development \[[@R47]\]. The identification of MEP synthase (which makes MEP from DXP) and downstream enzymes provided an impetus for synthetic preparations of MEP itself \[[@R48]\].

Although ME is produced in the leaves and flowers of some plants \[[@R49]\], and abiotically through the atmospheric oxidation of isoprene \[[@R50]-[@R52]\], discovery efforts in the MEP pathway necessitated access to multi-milligram quantities of the sugar. Prior to these efforts, no dedicated chemical syntheses of the sugar existed, although some syntheses of derivatives of ME had been reported \[[@R53]\]. A facile route to ME was reported by Duvold *et al.*in 1997, wherein ME was produced in 85% yield (80% e.e.) from 3-methylfuran-2(5H)-one **36** or 25% from citraconic anhydride **37**in four steps \[[@R54]\].

Sharpless asymmetric dihydroxylation was used to introduce the C-2 and C-3 hydroxyl groups with the correct stereochemistry into *cis*-olefin **38** to provide the diacetate **39** protected ME in excellent yield. Deprotection provided ME **40**in 80% yield over three steps from the furan 36 (Scheme **[10](#S10){ref-type="scheme"}**) \[[@R55]\]. This route also provided for the incorporation of heavy atom labels into the backbone of ME (as \[1,1,4,4-^2^H\]-ME) through reduction of the starting material with LiAlD~4~. Fontana and coworkers also reported a route to ME from dimethylfumarate (31% yield, 84% e.e., 6 steps) \[[@R56]\].

In this case, establishment of the correct stereochemistry of the hydroxyl groups was afforded through asymmetric epoxidation of the *trans*-alkene **44**to give epoxide **45**followed by ring opening with sodium hydroxide to provide the benzyl-protected ME **46**. Reduction of **46***via* hydrogenolysis over palladium gave ME **40**in moderate yield over eight steps (Scheme **[11](#S11){ref-type="scheme"}**). Heavy atom incorporation is also possible using this route, either in the form of deuterium (reduction with LiAlD~4~or similar reagent) or ^13^C (use of U-^13^C-dimethylfumarate). Asymmetric hydroxylation or epoxidation of 3-methylbut-2-enyl-1,4-diols to introduce the stereochemistry of the C-2 and -3 hydroxyl groups proved to be a facile and useful means that also found utility in the synthesis of MEP itself and a trifluorinated-derivative of ME \[[@R57]\]. Even more recently, a strategy to ME and its stereoisomers was published reliant upon this means to introduce hydroxyl functionalities \[[@R58]\], although the scheme largely utilizes methods previously reported in the synthesis of MEP \[[@R59],[@R60]\]. In another compelling application of the asymmetric dihydroxylation reaction in the context of branched carbohydrate synthesis, Taylor and coworkers described a two-step synthesis to ME **40** from 4-methyl 1,2-dioxine **47** (Scheme **[12](#S12){ref-type="scheme"}**) \[[@R61]\].

Central to this approach was generation of the dioxine intermediate diol **48** with the correct stereochemistry through photooxidation of a 1,3 butadiene precursor. Although the enantiomeric excess for the synthesis of ME using this method was somewhat low, the authors were able to produce a number of ME analogs with good yield and high enantioselectivity.

There are several reports for the enantiopure synthesis of ME. The use of protected carbohydrates as precursors to ME is a particularly effective means to ensure enantiopurity. Kis *et al.*were among the first to report such a strategy in their synthesis of ME and MEP in 2000, wherein 1,2:5,6-di-*O*-isopropylidene-D-mannitol was converted to ME in 10 steps or MEP in 13 steps \[[@R62]\]. In 2003, Hoeffler *et al.*reported the synthesis of enantiopure ME in 43% yield over 8 steps from 1,2-*O*-isopropylidene-α-D-xylofuranose **49** \[[@R63],[@R64]\]. In the authors' strategy, the 2-methyl functionality in the final product was introduced into a TBDPS-protected 1,2-*O*-isopropylidene-α-D-xylofuranose **50** by oxidation of the secondary alcohol to ketone **51**, followed by methyl-Grignard addition to the less hindered face of the carbohydrate ring to provide the carbon backbone **52** in the correct stereochemistry. Multiple high yielding deprotection/protection steps (**53-55**) followed by periodate cleavage and aldehyde **56**reduction then debenzylation of the penultimate intermediate **57** resulted in the final ME **40** product (Scheme **[13](#S13){ref-type="scheme"}**).

In this manner, the authors were able to exclusively obtain the desired diastereomer of the branched chain sugar. As with similar reports, incorporation of deuterium or tritium labels into the final product was enabled in the strategy.

Coates and coworkers have reported a versatile synthesis of ME, MEP and cMEPP from D-arabitol as the starting material \[[@R65],[@R66]\]. In the authors' strategy, benzylidene-protected D-arabitol **58**was first converted to 1,3-benzylidene-D-threitol **59** and subsequently transformed to (2*S*,4*R*)-*cis*-2-phenyl-4-*tert*-butyldimethyl-silyloxy-1,3-dioxan-5-one **61** in two steps. The dioxanone intermediate was selectively alkylated on the axial face (20:1) with methylmagnesium bromide to form the methyltetrol **62**core of ME and related metabolites. The final product is generated by silyl-deprotection to provide **62** then hydrogenolysis to enantiopure ME **40**(8% overall yield from D-arabitol in 9 steps), or alternatively **62** may be further modified to form MEP or cMEPP (Scheme **[14](#S14){ref-type="scheme"}**). Furthermore, the novel methylerythritol analogue, 1-amino-1-deoxy-2*C*-methylerythritol was also produced using this approach \[[@R65]\]. Lai and coworkers have reported modifications to this dioxanone strategy which resulted in a shorter synthesis with a slightly higher yield (7 steps, 11.5% overall yield) \[[@R67]\]. A similar strategy of diastereocontrolled addition of an alkyl Grignard reagent into a protected ketone was used by Chattopadhyay and coworkers to provide a straightforward and economical route to ME and other methyltetrol isomers \[[@R68]\].

*Syntheses of 2C-methyl-D-erythritol 4-phosphate* **71**(MEP)-Similar to other MEP pathway intermediates, MEP was previously synthesized using an enzymatic approach through condensation of glyceraldehyde-3-phosphate and pyruvate \[[@R7],[@R55]\]. As was observed in the synthesis of ME, several chemical routes to the 4-phosphate MEP are reported, and similarly involve asymmetric dihydroxylation of substituted diols or utilization of carbohydrate starting materials. Poulter and coworkers demonstrated the synthesis of MEP using the former approach in 2000 and 2002 in their synthesis of MEP as a monosodium salt and free acid, respectively \[[@R60],[@R69]\].

The sodium salt of MEP was synthesized from 1,2-propane diol **64** in 7 steps with an overall yield of 32% (78% e.e.). Following silyl-protection **65** of the primary alcohol and oxidation to provide ketone **66**, the *cis*-configuration was installed through a Wittig-Horner olefination reaction to give *cis*-olefin **67**in excellent yield. Reduction of the ester and phosphorylation of primary alcohol **68**provided the phosphotriester **69**in 84% yield over the two steps. Dihydroxylation of the olefin **69** was conducted using the method of Sharpless after installation of the phosphotriester, which necessitated buffering of the standard reaction conditions with NaHCO~3~, to provide the protected MEP **70** in moderate yield \[[@R55],[@R70]\]. Conversion of the phosphomethylesters to the corresponding acids was accomplished with TMS-Br under acidic conditions, and MEP **71**as the monosodium salt was formed upon neutralization (Scheme **[15](#S15){ref-type="scheme"}**). Formation of MEP as the free acid is accomplished by introducing the phosphate functionality as a benzyl-protected triester, which is ultimately removed *via* hydrogenation over Pd/C. Hoeffler *et al.*used this strategy to install the phosphate moiety into MEP ultimately from an 1,2-*O*-isopropylidene-α-D-xylofuranose starting material using an approach inspired from the authors earlier work toward the preparation of ME (as discussed above) \[[@R64]\]. Similarly, both Fontana \[[@R71]\] and Koppisch and Poulter \[[@R69]\] utilized benzyl ester protected phosphate groups to form the free acid of MEP from approaches that were inspired by previous efforts of their respective teams.

Synthesis of MEP from various protected carbohydrates, as noted above, has been reported by a number of teams. Enantiopurity of the final product is ensured by utilization of the carbohydrate starting material, and their use also provides a convenient means to introduce isotopic labels. Enantiopure preparations of MEP as the sodium salt from 1,2:5,6-di-*O*-isopropylidene-D-mannitol proceeded in 9% yield over 14 steps (as compared to 32% over 7 steps) \[[@R72]\] and preparation of the free acid from 1,2-*O*-isopropylidene-α-D-xylofuranose proceeded in 32% yield over 7 steps (compared to 27% yield over 5 steps) \[[@R64]\]. More recent syntheses from carbohydrate-based starting material have also provided facile access to other metabolites based on an ME backbone (such as MEP or cMEPP) \[[@R65],[@R66]\] or in the synthesis of derivatives of MEP \[[@R73]\]. As mentioned earlier, a deprotected intermediate of the methylated dioxanone **72** in Coates and coworkers synthesis of ME from D-arabitol is readily phosphorylated by lithiation with *n*-BuLi followed by reaction with dibenzyl chlorophosphoridate to provide the benzyl-protected MEP **73**. Removal of the benzyl protecting groups *via* hydrogenation followed by treatment with ammonia provided MEP as the ammonium salt in good yield **71**(Scheme **[16](#S16){ref-type="scheme"}**) \[[@R65]\].

In 2007, Koumbis and coworkers devised a synthesis of MEP from D-arabinose acetonide **74** \[[@R74]\]. In this case, the authors converted the starting material into an erythritol acetonide by tosylation of the free hydroxyls followed by LiAlH~4~ reduction to form the 1, 4 diol **75**. Monoderivitization of the diol with various protecting groups was performed using a tin-mediated procedure developed for 1,3- and vicinal 1,2-diols resulted in a high ratio (5:1) of the desired monoprotected alcohol **76** \[[@R75]\]. Following benzylation of the free alcohol to to provide the fully protected **77**, silyl-deprotection **78** and phosphorylation as its benzylated derivative **79**was accomplished in over 90% yield. Deprotection *via* hydrogenation ultimately provided MEP **71** as its free acid in 37% yield over 7 steps (Scheme **[17](#S17){ref-type="scheme"}**). Crick and coworkers used a similar approach to synthesize enantiopure MEP as its free acid from 1,2-*O*-isopropylidene-α-D-xylofuranose \[[@R76],[@R77]\]. Similar to the syntheses described earlier, a dibenzyl protected phosphate moiety was key to formation of MEP as its corresponding free acid.

*Syntheses of 4-diphosphocytidyl-2C-methyl-D-erythritol* **83**(CDPME)*-*Relatively fewer synthetic procedures to CDPME **83** exist, and with the exception of a fully enzymatic approach \[[@R7]\], most depend significantly upon prior routes toward the synthesis of the free acid of MEP. Koppisch and Poulter reported the first synthetic preparation of CDPME in 2002 (Scheme **[18](#S18){ref-type="scheme"}**) \[[@R60]\]. In the authors' synthesis, the key step was coupling of MEP **82** (as a tributylammonium salt) with cytidine monophosphate **81**(as a triethylammonium salt) *via* activation of the phosphate **80**with trifluoroacetic anhydride and methylimidazole, respectively. This phosphoramidite based approach was originally developed in a synthesis of UDP-galactofuranose, but has been incorporated into most reported syntheses of CDPME as well \[[@R78]\].

Upon workup and purification using size exclusion chromatography, the ammonium form of CDPME **83** was synthesized from MEP in a single pot with an overall yield of 40%. This phosphoramidite based coupling strategy has been employed in most CDPME syntheses reported to date, with the most notable exception being an enzymatic coupling strategy to form CDPME with recombinant CDPME synthase (IspD) and synthetic MEP prepared from 1,2-*O*-isopropylidene-α-D-xylofuranose \[[@R77]\]. In a similar fashion, D-arabitol was used in the synthesis of CDPME by Lai and coworkers through phosphoramidite coupling of alkylammonium salts of MEP and CMP \[[@R67]\].

*Syntheses of 4-diphosphocytidyl-2C-methy-D-erythritol 2-phosphate* **90**(CDP-ME2P)-In this synthesis, the hydroxyl groups of benzylidene diol **84**(from a previous synthesis \[[@R66]\]) were phosphorylated, in a stepwise manner, with first dibenzyl phosphochloridate **85**then phosphorous trichloride in the presence of ethanol to provide the double phosphotriester **86**in good yield. Benzyl deprotection was performed by hydrogenolysis in one step to provide the diethylphosphate protected ME2P **87**in near quantitative yield. Triethylammonium cytidine monophosphate **88** was then activated to the phosphoramidite and coupled with the phosphoramidite of **87**to provide the phosphate-protected CDP-ME2P **89** in moderate yield. The diethyl phosphate moiety was deprotected using TMSI to provide CDP-ME2P **90**in 16% overall yield over five steps (Scheme **[19](#S19){ref-type="scheme"}**) \[[@R76]\].

Crick and coworkers also reported a route to the MEP intermediate CDP-ME2P from D-arabitol. In this work, the authors extended the synthetic route to ME/MEP developed by Urban sky *et al.* to form several benzylphosphoester or methylphosphoester derivatives of the aforementioned authors' key dioxanone intermediate. In one case, the tertiary hydroxyl of the dioxanone intermediate was converted to a dibenzylphosphoester with PCl~3~ and benzyl alcohol, while its primary hydroxyl was transformed into a methylphosphoester with dimethyl phosphochloridate/*n*-BuLi. Coupling of this product to CMP through formation of the CMP phosphoramidite was accomplished in the manner of previous syntheses albeit in low yield. A second strategy, wherein the bisphosphorylated dioxanone intermediate was formed as a benzylphosphoester (at the primary hydroxyl group) and ethylphosphoester (at the tertiary hydroxyl) was formed first, and upon hydrogenation over Pd/C, 2,4-bisphosphomethylerythritol was formed as the 2-ethylphos-phoester. Phosphoramidite coupling of this material with CMP proceeded smoothly, and upon deprotection yielded CDP-ME2P in good yield \[[@R76]\].

*Syntheses of 2C-methylerythritol 2,4-cyclodisphophate* **95**(cMEPP)- Cyclization of 4-diphosphocytidyl-2*C*-methyl-D-eryth-ritol 2-phosphate by cMEPP synthase generates 2*C*-methyl-D-erythritol 2,4-cylodiphosphate (MECDP) \[[@R9]\]. An efficient synthesis of cMEPP was reported by Giner and Ferris using 2*C*-methyl-D-erythritol 1,3-diacetate **91**as the starting material. The authors reported simultaneous phosphorylation of both the primary and tertiary alcohol through diisopropyl dibenzyl phosphite under basic conditions and in situ oxidation to provide the dibenzyl protected phosphate **92** in 75% yield. Hydrogenation proceeded cleanly to provide the deprotected phosphate **93**followed by phosphate coupling *via* carbodiimide cyclization **94** and acetate removal under careful basic conditions to provide the cyclic diphosphate **95**in four steps with 42% overall yield from the diacetate (Scheme **[20](#S20){ref-type="scheme"}**) \[[@R79]\].

A second, lengthier synthesis began with 1,3-benzylidene-D-threitol **96**. Following periodate cleavage, **97**was selectively protected with TBSCl at the primary alcohol to provide the monoether **98**. A phase-transfer-promoted RuO~4~ oxidation provided ketone **99**followed by reduction with methylmagnesium bromide **100**and removal of the protecting group yielding the benzylidene protected ME **101**. Double phosphorylation using phosphoramidite coupling instilled the two benzyl-protected phosphate esters **102**and selective debenzylation of the phosphate esters *via* hydrogenation provided the bis-phosphomonoester **103**, which was subsequently cyclized using 1, 1'-carbonyl diimidazole to provide the penultimate intermediate **104** \[[@R65],[@R66]\]. The final product, cMEPP **95**, was generated by simple hydrogenation over palladium hydroxide (Scheme **[21](#S21){ref-type="scheme"}**). This method required 9 steps as opposed to the 4 steps required in the previous synthesis and was also lower yielding (10% vs. 42%).

*Syntheses of*(*E*)*-4-hydroxydimethylallyl diphosphate***107**(HDMAPP)-This straightforward synthesis was reported independently by several research groups in rapid succession upon its initial discovery in 2002 \[[@R80]-[@R86]\]. Of the seven, three utilized a strategy to incorporate an isotopic tag in either penultimate or final step of the synthesis. The most efficient synthesis of non-radiolabeled HDMAPP was obtained in two steps from the commercially available 2-methyl-2-vinyloxirane **105**in 72% overall yield (Scheme **[22](#S22){ref-type="scheme"}**). Importantly, the (*E*)-geometry of the chloroalcohol **106**was preferred (97:3) upon ring opening in the presence of titanium (IV) tetrachloride as determined from nuclear Overhauser effects spectroscopy (NOESY) followed by diphosphorylation to provide HDMAPP **107**. From the identical starting material **105**, ring opening in the presence of cupric (II) chloride provided the chloroaldehyde **108**in moderate yield. Following conversion of the aldehyde to the methylacetal **109**, either a deuterium or tritium was introduced in the final step to provide labeled HDMAPP in 23% or 15% yield, respectively \[[@R85]\].

Fox and Poulter demonstrated the (*E*)-chloroaldehyde as a versatile intermediate for insertion of an isotopic label to C-1 in the penultimate step of the synthesis (Scheme **[23](#S23){ref-type="scheme"}**). The overall yield for reduction of the intermediate chloroaldehyde **108**to the chloroalcohol **106**followed by phosphorylation provided HDMAPP **107**, with purification of the intermediate olefin, were 66% \[[@R87]\].

*Isopentenyl diphosphate and dimethylallyl disphosphate*(IPP and DMAPP)-Both IPP and DMAPP are derived from HDMAPP, where the MEP pathway is operative, by reductive elimination of water \[[@R88]\] and represent the requisite building blocks to all isoprenoids. The synthesis of both compounds was optimized in the mid-80s by Davisson and Poulter during their investigations for improving the diphosphorylation step of the allylic **110**or non-allylic **111**prenyl alcohols over previously published reports \[[@R89]\]. Briefly, the authors found that when pyrophosphoric acid was treated with tetra-*n*-butyl ammonium hydroxide and immediately lyophilized, tris(tetra-*n*-butyl) ammonium hydrogen pyrophospate was obtained on a multigram scale at near quantitative yields for the displacement reaction with the corresponding activated allylic **112** and nonallylic **113** prenyl moieties. Following cation exchange and cellulose chromatography, the ammonium form for prenyl disphosphates, **114**and **115**, were typically obtained in excess of 75% yield on gram scales and could be stored for long durations under cool temperatures with minimal decomposition (Scheme **[24](#S24){ref-type="scheme"}**) \[[@R90],[@R91]\].

ISOPRENOIDS
===========

Monoterpenes
------------

Monoterpenes, which comprise the C~10~ class of isoprenoids, are largely derived from condensation of IPP to DMAPP in either a 'head-to-tail' or 'non-head-to-tail' fashion or, alternatively, through condensation of two DMAPP monomers. These enzyme-catalyzed reactions ultimately result in the extremely large structural diversity observed within this class of compounds \[[@R92]-[@R94]\]. They are often found in pesticides, essential oils, fragrances, for use in homeopathic medicine, and are commonly used building blocks to higher-value chemicals, thus demonstrating their utility for industrial applications \[[@R95],[@R96]\]. There are countless reports in the literature for the chemical syntheses of the acyclic, mono- and bicyclic monoterpenes and the reader is directed to several sources for reviewing synthetic approaches to these industrially useful compounds \[[@R97]-[@R101]\]. Some common monoterpenes are found in (Fig. **[1](#F1){ref-type="fig"}**) and a few representative examples for their syntheses are presented.

The cyclic monoterpene, (+)-limonene, is derived from cyclization of GPP and has proven to be an essential building block toward the synthesis of dozens of closely related compounds. Further, limonene is primarily accessed through cold-pressed orange oil on large scales, making this monoterpene a rather inexpensive chiral starting material suitable for chemical synthesis, and is therefore utilized as building blocks to dozens of related compounds. Representative examples of these chemical transformation are found in a review by Thomas and coworkers and some basic chemical transformations from limonene found in (Fig. **[2](#F2){ref-type="fig"}**) \[[@R102]\]. Another common bicyclic monoterpene, camphor, is found in the wood of camphor trees and is most often utilized as a plasticizer in certain materials, for therapeutics, as a wax, and as an aromatic fragrance in essential oils. The synthesis of camphor from α-pinene was first demonstrated in 1922 and served as a building block for hundreds of chemical transformations to related isoprenoid derivatives \[[@R103]\].

Among bicyclic monoterpenes, α- and β-pinenes are among the most widely distributed of the isoprenoid family and are found in the essential oils of most trees. They are currently of industrial importance as solvents and for the commercial preparation of camphor and α-terpinol \[[@R104]\]. However, the bicylic system of pinene presented a synthetic challenge. Fallis and coworkers addressed this through utilization of a bicyclic heptane system common to many monoterpenes within this structural class of isoprenoids. Following several high-yielding steps to convert ester **116**to the well-known Hagemann's ester **117**, transformation to the dimethyl keto acetate **118** then tosylation to **119**provided a convenient leaving group for base-assisted cyclization to provide the bicyclic core **120**. A Wittig reaction with methylenetriphenylphosphorane and **120** yielded β-pinene **121**, which was subsequently isomerized to α-pinene **122** by hydrogenation over palladium/carbon (Scheme **[25](#S25){ref-type="scheme"}**) \[[@R105]\]. All chemi-cal transformations were in excess of 70% yield, making this strat-egy to this class of compounds useful for large scale production.

Another, more facile synthesis to β-pinene was developed by Snider *et al.* using a stereospecific \[2+2\] cycloaddition of ketenes to alkenes. In this synthesis, the authors converted geranic acid **123** to the corresponding acid chloride **124**. This was a versatile intermediate since the presence of the electron-withdrawing halogen enabled formation of the ketene **125**with the necessary regiochemistry for subsequent cyclization to the vinyl ketones. β-Pinene **121** was generated from the ketene through a Wolff-Kishner reduction or to the monoterpene, chrysanthenone **126**, through simple isomerization (Scheme **[26](#S26){ref-type="scheme"}**) \[[@R106]\].

The bicyclic monoterpene, carene, is one of the major constituents in turpentine \[[@R107]\]. In one synthesis, the cyclic hexene group was constructed from isoprene **127** and ketone **128** by a Diels-Alder reaction to form the methylated cyclohexene regioisomers **129**and **130**. Following methyl addition to the ketone to provide a racemic mixture of tertiary alcohols **131**and **132** the bicyclic product, 3-carene **133**, and the methyl regioisomer **134** were obtained using thionyl chloride (Scheme **[27](#S27){ref-type="scheme"}**) \[[@R108]\]. This synthesis is useful since 3-carene is used for the construction of other monoterpenes and cyclopropanes. A detailed account of synthetic approaches to new monoterpenes using carene as the building block are found in a recent review \[[@R109]\].

Whereas there are countless numbers of chemical syntheses to monoterpenes and their structural derivatives, many are traced back to a few, basic mono- and bicyclic compounds. There are dozens of reviews, manuscripts and books readily available that enable a detailed understanding of the evolution for chemical approaches to a myriad of monoterpenes and those presented in this review are meant to serve as a nucleation point for future synthetic efforts.

Sesquiterpenes
--------------

Sesquiterpenes, which comprise the C~15~ class of isoprenoids, are predominantly derived from the condensation of an additional IPP monomer to the C~10~monoterpene framework to provide farnesyl diphosphate (FPP). They are a structurally diverse group where all are derived from FPP *via* differing enzyme-catalyzed cyclization reactions and carbon skeleton rearrangements. They are commonly found as essential oils in plants in the mono-, bi- and tricyclic forms and have been shown to have a wide range of biological activities \[[@R110]\]. However, in spite of the expansive structural diversity, it is the acyclic form that has garnered the most attention from a synthetic chemistry perspective. Briefly, previous studies have demonstrated that mammalian Ras proteins, when farnesylated, result in cellular signal transduction leading to normal cell growth, differentiation and survival. However, mutant Ras-proteins that are always activated result in undifferentiated cell growth and are now implicated in greater than 30% of human cancers \[[@R111],[@R112]\]. The enzyme responsible for farnesylation (prenylation) of Ras, protein farnesyltransferase (PFTase), when inhibited resulted in reversion of the undifferentiated cell growth to a normal cell. Hence, synthesis of FPP analogs as anti-cancer therapeutics is an area of intense research \[[@R113]\]. Primary to this goal was the synthesis of suicide inhibitors against PFTase to prevent farnesylation through covalent attachment of the FPP analog to the enzyme by trapping a carbocation intermediate within the enzyme active site \[[@R114]\].

A primary concern in the synthesis of farnesyl diphosphate analogs is maintenance of the requisite all *trans*-isomer in the final product. Gibbs and co-workers designed multiple synthetic routes to both the 3- and 7-vinyl substituted farnesyl diphosphate (VFPP) analogs through the vinyl triflate intermediate **136** *via* a ketone ester **135**to provide the *E*-isomer **137** with high stereoselectivity (16:1) and in good yields \[[@R115]\]. Reduction, alcohol activation and diphosphorylation provided the all *E*-isomer of 3-VFPP **138**(Scheme **[28](#S28){ref-type="scheme"}**). This synthetic approach was also implemented in the synthesis of the all *E-*7-VFPP analog; albeit, in much lower yields since two coupling steps using the vinyl triflate strategy were necessary, required 11 steps and less than 10% overall yield \[[@R116]\].

In a recent report, Gibbs *et al.*improved on their synthesis of 7-VFPP by coupling of 5-lithio-2, 3-dihydrofuran **139** with an isoprenylorganocuprate **140** to provide the corresponding alkenylcuprate intermediate **141**. This compound proved to be a versatile intermediate since this affords the opportunity to introduce multiple functional groups into ultimately the 7-position of FPP. Following conversion of **141** into the corresponding organozinc intermediate **142**over four steps in 25% yield, the vinyl-substituted farnesyl skeleton was completed *via* coupling to the silyl-protected vinyl iodide **143** through palladium triphenylphosphine and removal of the silyl-protecting group to provide 7-vinylfarnesol **144**. Diphosphorylation provided 7-VFPP **145**over six steps in 12% overall yield (Scheme **[29](#S29){ref-type="scheme"}**) \[[@R117]\].

Diterpenes
----------

Diterpenes, which comprise the C~20~ class of isoprenoids, are derived from condensation of IPP to FPP to form geranylgeranyl diphosphate (GGPP). Some representative examples include, dolichols, ubiquinones (plastoquinones), phytyl derivatives and geranylgeranylated proteins \[[@R118]\]. The structural diversity is amplified through multivariant cyclizations *via* carbocation intermediates and alkyl shifts to provide mono-, di-, and tricyclic compounds, which are further processed depending on organismal need. As a result of this diversity, it is not surprising that there are greater than 11,000 diterpenes that have been identified \[[@R119]\]. Therefore, in a similar vein as with the sesquiterpenes, this section will provide some representative examples for the chemical syntheses of GGPP analogs since there is ongoing interest for identifying novel compounds for medicinal purposes.

One class of inhibitors consists of the nitrogen-containing bisphosphonates, which are used in treating bone resorption diseases such as osteoporosis and metastatic bone disease \[[@R120]\]. These bisphosphonates work by depleting cells of GGPP, leading to inhibition of protein isoprenylation \[[@R121]\]. In order to determine the exact mechanism by which bisphosphonates inhibit isoprenoid metabolism, a GGPP analog was synthesized using a synthetic scaffold that is amenable to varying isoprenoid chain lengths. A facile synthesis for one of the bisphosphonates containing the geranyl substituent is described below.

Treatment of tetraethyl methylenebisphosphonate **146** with sodium hydride, 15-crown-5 ether, and farnesyl bromide **147** provided the dialkylated bisphosphonate **148** product harboring the geranyl moieties. Although not high yielding, the mono- or dialkylation product could be regulated through careful titration with the base \[[@R122]\]. Deprotection of **148** with TMS-Br provided the GGPP analog **149**in 95% yield (Scheme **[30](#S30){ref-type="scheme"}**). This strategy has proven successful for addition of alkylation reagents of varying chain length.

In addition to the bisphosphonates, another strategy using GGPP analogs was hypothesized for inhibition of GGPP synthase. One of the reasons for developing this alternative synthetic route was the observation that bisphosphonates tend to be poorly absorbed into the body through oral delivery. Creating compounds that have increased hydrophobicity was postulated to have better absorption properties \[[@R120]\]. Based upon biochemical evidence that a developing carbocation intermediate was formed within the enzyme active site of GGPP synthase the aza analog of GGPP was necessarily synthesized.

In the synthesis of an aza-GGPP **155**, alkylation of farnesyl chloride **150** with α-lithio formamidine **151**generated an amidine, which was subsequently hydrolyzed to a farnesyl-*N*-methylamine **152**. Alkylation of the amine with *t*-butylbromoacetate resulted in the β-aminoester **153**in excellent yield. Following reduction of **153**with lithium aluminum hydride, the resulting geranylgeraniol *N*-methylamine **154** was converted to the corresponding diphosphate with methanesulfonyl chloride and tris(tetrabutylammonium) hydrogen pyrophosphate to provide aza-GGPP **155**over four steps in 30% yield from commercially available farnesyl chloride (Scheme **[31](#S31){ref-type="scheme"}**) \[[@R123]\].

As described previously, several FPP analogs were synthesized by Gibbs and Wiemer using a novel palladium, copper-catalyst coupling approach. This concept was expanded by Coates *et al.*to synthesize new GGPP analogs thought to act as inhibitors of PGGTase I, which attaches a geranylgeranyl moiety from GGPP to a cysteine in a CAAX-type box, where leucine is the carboxyl terminal residue \[[@R124]\]. Three new GGPP analogs were synthesized containing phenyl, *tert-*butyl and cyclopropyl substituents. The phenyl-substituted GGPP analog was prepared from an ethyl acetoacetate dianion **156** coupled with farnesyl bromide **157** to provide the β-ketoester **158**. The potassium enolate was then transformed into the vinyl triflate **159**. Coupling of the triflate with phenylboronic acid and silver oxide as the base yielded the desired phenyl ester **160**. Reduction of the ester with DIBALH and subsequent phosphorylation provided 3-PhGGPP **162** over six steps in 11% yield (Scheme **[32](#S32){ref-type="scheme"}**) \[[@R125]\].

Triterpenes
-----------

Triterpenes comprise the C~30~class of isoprenoids and are biosynthesized through the condensation of two farnesyl diphosphate (FPP) units followed by reduction. The majority of triterpenes in biological systems result from 'head-to-head' condensations of FPP, which result in a linkage between the first carbons in each respective farnesyl group (a 1'-1 linkage). There are other examples of triterpenes with varied linkages in nature and one such triterpene, botryococcene (1'-3 linkage), will be discussed later in this section.

The linear triterpene, squalene, is a key precursor in the biosynthesis of cholesterol and other steroids. During the condensation of FPP monomers in the biosynthesis of squalene, a cyclopropyl diphosphate intermediate (presqualene diphosphate or PSPP) is formed and subsequently reduced by NADPH to form the final product \[[@R126]\]. Squalene itself then is transformed into the fused tetracyclic core characteristic of sterols and steroids. The synthesis of sterols, steroids, and other cyclic triterpenes represents a large body of information and is beyond the scope of this review. In this section, we will summarize approaches to construction of several representative linear triterpenes. Readers with an interest in cyclic triterpenes are directed to other comprehensive reviews.

An early synthesis of squalene was based on systematic olefin synthesis. In step 1, The five-carbon and six-carbon building blocks for the external segments of squalene were derived from α-acetyl-α-chlorobutyrolactone **163** to generate homoallylic chloride **164**and 3,5-dichloropentan-2-one **165**over four steps. Coupling of the C-5 and C-6 fragments with *n*-BuLi provided the homogeranyl backbone **166**. Following epoxidation and elimination, the resulting homogeranyl chloride **167** was ready for squalene synthesis.

Step 2 entailed utilizing ketone **165**as the starting material for the synthesis of the internal segment of squalene. Briefly, following ketalization of **165**to generate 1, 3-dioxolane **168**, coupling with*t*-butyl acetoacetate **169**and deprotection provided the central segment, 3,6-dichlorooctane-2,7-dione **170**, for squalene assembly. Condensation of the products from steps 1 and 2 were accomplished by treatment of two equivalents of homogeranyl chloride **167** with two equivalents of *n*-BuLi and one equivalent of dione **170** to provide the dicholorosqualene intermediate **171**. Subsequent epoxidation and oxygen elimination as employed in the construction of homogeranyl chloride provided squalene **172** in 15 steps (Scheme **[33](#S33){ref-type="scheme"}**); however, yields for this synthesis were not estimated \[[@R127]\].

One challenge in the chemical synthesis of squalene is stereoselectivity, as all bonds are found in the *trans*-configuration. In a later synthesis, a stereoselective Claisen rearrangement was employed. Starting with succinaldehyde **173**, treatment of the resulting alcohol with *i*PrMgBr yielded bis-allylic alcohol **174** in good yield. The alcohol was subject to a Claisen rearrangement with 3-methoxyisoprene **175** to the C-20 tetraenedione **176**, which was subsequently reduced with sodium borohydride to provide the tetraenediol **177**. Repetition of this sequence of reactions provided the C-30 squalene **178**backbone. Rearrangement of the terminal double bonds and elimination of the alcohol groups were accomplished through the use of thionyl chloride in a substitution reaction to provide the terminal halides **179**, whereupon reduction with lithium aluminum hydride yielded squalene **172** over eight steps in 7% yield (Scheme **[34](#S34){ref-type="scheme"}**) \[[@R128]\].

As mentioned previously, linear, branched triterpenes (such as those with 1'-3 isoprenoid linkages) are also found in nature. The best example of a triterpene of this nature is botryococcene, which is produced and accumulated by the B race of the green algae from which its name is derived, *Botryococcus braunii* \[[@R129]-[@R131]\]. The most abundant of the hydrocarbons in *B. braunii* Race B is the tetramethylated derivative of the triterpene, C-34 botryococcene \[[@R132]\]. This compound is of special interest since it was demonstrated the botryococcenes are compatible with existing oil infrastructures and, following hydrocracking, can be used directly as a 'drop-in' fuel \[[@R133]\].

The chemical synthesis of the tetramethylated botryococcene is challenging since there are six stereocenters on the carbon framework. To the best of our knowledge, there is only a single published report for the total synthesis of this isoprenoid with the correct stereochemistry in the final product, although there are several reports of the C-30 botryococcene and related analogs chemical synthesis \[[@R134]-[@R137]\]. Certainly, considering the interest in botryococcenes as a source of biofuel, novel synthetic approaches to the methylated versions may prove fruitful in order to study the enzyme(s) responsible for methylated botryococcene biosynthesis. Briefly, White *et al.*recognized the symmetry elements present in the structure and thus devised a convergent strategy for condensing the two symmetric fragments with the core segment to provide the correct stereochemistry in the final product. Specifically, as outlined in (Scheme **[35](#S35){ref-type="scheme"}**), Step 1, the synthesis of the symmetric fragment began with a five step approach from methyl (2*S*)-3-hydroxy-2-methylpropionate **180**to the homoallylic alcohol **181** in 29% yield. Head-to-tail union of **181** proceeded through coupling of the dilithio species **182** with the tosylated alcohol **183** to provide the enantiomerically pure C~12~ segment **184** in excellent yield.

The synthesis of the central subunit proved to be much more challenging. The primary concern was introduction of a quaternary carbon center with the requisite *R*-configuration in the core fragment. Starting with *R*-methyl ester **185**, conversion to the pivotal intermediate methoxymethyl ester **186**was accomplished in six steps in good yields. Installation of the quaternary center with the correct stereochemistry was accomplished by γ-deprotonation and 1,4-elimination of the methoxymethyl ester **187**to provide a 3:2 diastereomeric mixture of ester **188**. The authors then used an enantioconvergent strategy to convert both diastereomeric intermediates to the central fragment through alternating protection and deprotection strategies to provide the enantiomerically pure diiodide central subunit **190** over thirteen steps in 7% yield. Activation of homoallylic alcohol **184**required four steps to the cuprate **191** intermediate and enabled coupling of the core fragment **190** to provide (--)-C~34~-botryococcene **192**over five steps in 8% yield (Scheme **[35](#S35){ref-type="scheme"}**) \[[@R138]\].

Tetraterpenes
-------------

Tetraterpenes, which comprise the C~40~class of isoprenoids, are derived from two C~20~ geranylgeranyl disphosphates in a head-to-head condensation reaction. Representative examples include the carotenoids and xanthophylls, which have strong anti-oxidant properties and are essential components in photosynthetic machinery \[[@R139]\]. Further, carotenoids are used extensively in the food and cosmetic industries as food colorants, protection against UV-irradiation, and as nutritional supplements \[[@R140],[@R141]\]. Although the majority of tetraterpenes are isolated from biological sources, the structural complexity of these isoprenoids proved to be a synthetic challenge largely due to the extensive double bond network and introduction of the correct stereochemistry at remote positions along the carbon framework. Two representative examples for achieving this end are presented.

Lycopene is an acyclic tetraterpene and the immediate precursor to both α- and β-carotene that consists of 13 double bonds all in the *trans*-configuration. This compound's high radical scavenging ability in addition to being synthetically challenging were major drivers toward lycopene synthesis \[[@R142]\]. A favorable synthetic route to the all *trans*-lycopene exploited two Wittig-Horner reactions to introduce double bonds under mild reaction conditions. The starting material, 4,4-dimethoxy-3-methylbutanal **193**, was condensed with methylene bisphosphonic acid tetraethyl ester **194** in the presence of NaH to provide the C~6~ propenyl phosphonate **195**. Wittig-Horner condensation with the methyl heptenone **196** yielded the dimethoxytriene **197** in the correct double bond configuration. Following deprotection under acidic conditions, aldehyde **198** was condensed with the identical biphosphonic acid **194**to provide the all-*E*-tetraene **199**. Another Wittig-Horner reaction with diketone **200**provided the all *trans*-lycopene **201**over five steps in 27% yield (Scheme **[36](#S36){ref-type="scheme"}**) \[[@R143]\].

Lutein is a xanthophyll found in plants for non-photochemi-cal quenching of singlet excited state chlorophyll, which occurs at high light intensities, thus prevents photoinhibition. In addition, lutein is a major dietary carotenoid abundant in fruits and vegetables. The predominant stereoisomer is (*3R,3'R,6'R)*-β,ε-carotene-3,3'-diol \[[@R144]\]. The strategy used in one synthesis to make this isomer (and others) was to couple C-15 and C-10 building blocks, then elongate the resulting C-15 hydroxyaldehyde through a Wittig salt intermediate. Commercially available α-ionone **202** was the starting material for the synthesis of nitrile **203**, which enabled facile chain elongation. Selective oxidation of **203** to the corresponding conjugated ketone **204** was accomplished in the presence of peroxide and bleach. Careful reduction of the ketone in the presence of borohydride provided racemic alcohol **205**in excellent yield. Reduction of the nitrile moiety to the aldehyde **206** using DIBAL-H resulted in the racemic mixture of hydroxyaldehydes. To isolate the desired (*3R, 6R*) configuration, kinetic resolution of **206** was employed using an enzyme-mediated acylation through Lipase AK. Fortunately, the desired stereoisomer **207**remained unreactive and was readily purified from the acylated enantiomer. The aldehyde was subjected to olefination using the protected Wittig salt **208**harboring the C~10~ internal portion of the lutein carbon framework resulting in a mixture of *cis*- and *trans*-configured **209**products. Following deprotection of the acetal to provide aldehyde **210**, coupling with a second Wittig salt reagent **211**appended to the remaining lutein framework provided a mixture of *cis*- and *trans*-lutein **212**. The diastereomeric lutein was isomerized under refluxing conditions and isolated *via* column chromatography and crystallization resulting in stereomerically pure (*3R,3'R,6'R*) lutein **213**in 6% yield over nine steps (Scheme **[37](#S37){ref-type="scheme"}**) \[[@R145]\].

SUMMARY
=======

Isoprenoids are a tremendous illustration of the cornucopia of chemical diversity and unique biochemical roles that are possible within members of a single molecular family. A detailed understanding of these structures, and of their roles, is empowered by the development of synthetic methodologies to produce the corresponding target molecules, and as substrates or products for detailed enzymological studies. In nature, the biosynthesis of isoprenoids affects the conversion of small molecule acids (such as those used in the mevalonate pathway) or carbohydrates (such as those used in the methylerythritol phosphate pathway) into molecules that are largely aliphatic hydrocarbons. Similarly, as is outlined in our review, the synthetic methodologies to produce a given isoprenoid may draw from and utilize chemical reactions associated with the construction of hydrocarbons, carbohydrates, or diphosphate based bioconjugates.

Whereas the biological production of isoprenoids will likely be the major route to these compounds, chemical synthesis of isoprenoids and their corresponding precursors will always be necessary. This is especially relevant when probing enzyme activity thus requiring the synthesis of substrate analogs. Emphasis on the chemical syntheses of MEP pathway intermediates to isoprenoids was a result of the exhaustive efforts required to probe the enzyme function responsible for tens of thousands of natural products that are found in all corners of life. It is also important to highlight the potential of longer chain isoprenoids for use in industrial applications, including nutracueticals, pharmaceuticals, cosmetics and as a source for biofuels due to the energy rich composition of these important compounds.
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